New, fast-acting medication to treat depression
SPRAVATO® (esketamine) CIII, is the first FDA approved ketamine nasal spray for use in treating adults with treatment resistant depression (TRD) and major depressive disorder (MDD).
As a certified treatment center, our medical staff have been trained to prescribe, dispense and administer SPRAVATOTM and have established processes and procedures in accordance with the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. A healthcare provider will provide direct supervision as the patient self-administers SPRAVATO® and will monitor every patient after every dose for at least two hours for resolution of sedation and dissociation and changes in vital signs. SPRAVATO® can only be administered at healthcare settings certified in the REMS Program and to patients enrolled in the program.